Skip to main content

Table 3 Proportion of treated comorbid conditions

From: Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases – a claims data analysis

Share of diagnosed individuals with comorbidity-relevant prescription at baseline
  N diagnosed N treated % treated
Congestive heart failure (EI group 1) 10,793 9514 88.1
 Beta-blockers 5093 53.5
 ACE inhibitors 3995 42.0
 Angiotensin-I-antagonists 1752 18.4
 Digitalis glycosides 1038 10.9
 Diuretic drugs 5114 53.8
Cardiac arrhythmia (EI group 2) 9694 5382 55.5
 Beta-blockers 4769 88.6
 Digitalis glycosides 1256 23.3
 Anti-arrhythmic drugs 512 9.5
Valvular disease (EI group 3) 5345 3957 74.0
 Beta-blockers 2536 64.1
 ACE inhibitors 1806 45.6
 Diuretic drugs 2691 68.0
IHD 11,632 9357 80.4
 Statins 3761 40.2
 Beta-blockers 5730 61.2
 ACE inhibitors 4292 45.9
 Angiotensin-I-antagonists 1971 21.1
 Antiplatelet drugs 2986 31.9
 Heparin (−derivates) 1157 12.4
 Vitamin-K antagonists 1187 12.7
Hypertension without complications (EI group 6) 19,059 17,594 92.3
 Beta-blockers 7255 41.2
 ACE inhibitors 6433 36.6
 Angiotensin-I-antagonists 3241 18.4
 Diuretic drugs 4936 28.1
Hypertension with complications (EI group 7) 5866 5301 90.4
 Beta-blockers 2813 53.1
 ACE inhibitors 2221 41.9
 Angiotensin-I-antagonists 1222 23.1
 Diuretic drugs 2427 45.8
PH 4537 1771 39.0
 PAH drugs 237 13.4
 Diuretic drugs 1699 95.9
COPD (EI group 10) 20,595 9473 46.0
 LABA 2431 25.7
 LAMA 4376 46.2
 ICS 2138 22.6
Peripheral vascular disorders (EI group 4) 6692 3391 50.7
 Antiplatelet drugs 1566 46.2
 Heparin (−derivates) 698 20.6
 Vitamin-K antagonists 581 17.1
 Statins 1928 56.9
Diabetes without complications (EI group 11) 6403 2505 39.1
Diabetes with complications (EI group 12) 5025 3337 66.4
Depression (EI group 31) 7410 2656 35.8
GERD 5594 3629 64.9
 PPI 3545 97.7
 Histamin-H2 antagonists 5594 99 2.7
  1. percentages at substance level refer to the treated population
  2. EI Elixhauser Comorbidity Index